Pfizer and BioNTech announced Omicron-adapted COVID-19 vaccine candidates demonstrated high immune response
On Jun. 24 2022, Pfizer and BioNTech announced positive data evaluating the safety, tolerability, and immunogenicity of two…
-
-
BioNTech started construction of first mRNA vaccine manufacturing facility in Africa
On Jun. 23, 2022, BioNTech announced it had reached a milestone in the establishment of scalable mRNA vaccine…
-
Pfizer and BioNTech provided update on rolling submission to EMA for potential variant-adapted vaccine
On Jun. 15, 2022, Pfizer and BioNTech announced the European Medicines Agency (EMA) had initiated a rolling review…
-
Pfizer and BioNTech received positive CHMP Opinion for COVID-19 vaccine booster in adolescents 12 through 17 years of age in EU
On Feb. 24, 2022, BioNTech announced that the Committee for Medicinal Products for Human Use of the European…
-
BioNTech introduced first modular mRNA manufacturing facility to promote scalable vaccine production in Africa
On Feb. 16, 2022, BioNTech announced it had introduced its approach to establishing scalable vaccine production by developing…
-
Pfizer and BioNTech updated rolling submission for EUA of COVID-19 caccine in children 6 months through 4 years of Age
On Feb. 11, 2022, Pfizer and BioNTech announced plans to extend their rolling submission to the U.S. Food…
-
Pfizer and BioNTech initiated rolling submission for EUA of COVID-19 vaccine in children 6 months through 4 years of age
On Feb. 1, 2022, Pfizer and BioNTech announced that following a request from the U.S. Food and Drug…
-
Merck and Ridgeback’s Molnupiravir, investigational antiviral COVID-19 medicine, demonstrated activity against Omicron variant
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
-
Pfizer and BioNTech initiated study to evaluate Omicron-based COVID-19 vaccine in adults 18 to 55 years of age
On Jan. 25, 2022, Pfizer and BioNTech announced the initiation of a clinical study to evaluate the safety,…
-
Pfizer and BioNTech published data from two studies on COVID-19 vaccine-induced antibodies ability to neutralize SARS-CoV-2 Omicron variant
On Jan. 24, 2022, Pfizer and BioNTech announced the publication of new results from two laboratory studies demonstrating…
-
Mixed vaccine schedules offered strong booster responses after two doses of CoronaVac vaccine
On Jan. 24, 2022, the University of Oxford announced that a third booster dose of either the ChAdOx1…
-
Positive results of Pfizer’s phase 3 study exploring co-administration of PREVNAR 20 with Pfizer-BioNTech COVID-19 vaccine released
On Jan. 12, 2022, Pfizer announced positive top-line results from a Phase 3 study describing the safety and…
-
BioNTech and InstaDeep developed and successfully tested early warning system to detect high-risk SARS-CoV-2 variants
On Jan. 11, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration had expanded the…
-
Pfizer and BioNTech signed global collaboration agreement to develop first mRNA-based shingles vaccine
On Jan. 5, 2022, Pfizer and BioNTech announced a new research, development and commercialization collaboration to develop a…
-
Pfizer and BioNTech received U.S. FDA EUA of COVID-19 vaccine booster for individuals 12 years of age and older
On Jan. 3, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration had expanded the…
-
Pfizer and BioNTech submit updated longer-term follow-up data of COMIRNATY in adolescents to EMA
On Dec. 23, 2021, Pfizer and BioNTech announced that they had submitted longer-term follow-up data from the companiesﾒ…
-
Pfizer and BioNTech provided EU more than 200 million additional doses of COMIRNATY for vaccine supply
On Dec. 20, 2021, Pfizer and BioNTech announced an agreement had been reached with the European Commission (EC)…
-
Pfizer and BioNTech received U.S. FDA EUA of COVID-19 vaccine booster for individuals 16 years and older
On Dec. 9, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
-
Follow-up data from phase 3 trial of Pfizer-BioNTech COVID-19 vaccine supported safety and high efficacy in adolescents 12 through 15 years of age
On Nov. 22, 2021, Pfizer announced topline results from a longer-term analysis of the safety and efficacy of…
-
FDA announced FDA authorization of Moderna’s booster dose of COVID-19 vaccine in the U.S. for adults 18 years and older
On Nov. 19, 2021, the U.S. Food and Drug Administration (FDA) announced that it had extended the emergency…
-
Pfizer and BioNTech received expanded U.S. FDA EUA of COVID-19 vaccine booster to include individuals 18 and older
On Nov. 19, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
-
EU to donate more than 70 million doses of Moderna COVID-19 vaccine to COVAX to fight COVID-19 pandemic in low income countries
On Nov. 16, 2021, an agreement was announced that enabled the European Union and European Economic Area countries…
-
Zipline, Pfizer and BioNTech paved way for automated, on-demand delivery of first mRNA COVID-19 vaccines in Ghana
On Nov. 11, 2021, Zipline, Pfizer and BioNTech announced that Zipline had successfully completed the first long-range drone…
-
Pfizer and BioNTech received first U.S. FDA EUA of COVID-19 vaccine in children ages 5 through 11 years
On Oct. 29, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had authorized…
-
Pfizer and BioNTech provided U.S. Government an additional 50 million pediatric doses of COVID-19 vaccine
On Oct. 28, 2021, Pfizer and BioNTech announced that the U.S. government had purchased 50 million more doses…
-
BioNTech planned to initiate construction of an mRNA vaccine manufacturing facility in Africa in mid-2022
On Oct. 26, 2021, BioNTech announce that the Company planned to initiate the construction of the first state-of-the-art…
-
FDA Advisory Committee votes in favor of granting EUA for Pfizer-BioNTech Covid-19 vaccine in children 5 to <12 years
On Oct. 26, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administrationﾒs (FDA) Vaccines and…
-
COVID-19 infection presents greater risk of causing very rare neurological events than vaccines
On Oct. 25, 2021, scientists at Oxford University reported that Infection with COVID-19 carried a much higher risk…
-
The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employees
On Oct. 22, 2021, the U.S. Department of Veterans Affairs (VA) announced that it had begun offering Moderna…
-
Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccine
On Oct. 21, 2021, Pfizer and BioNTech announced topline results from a Phase 3 randomized, controlled trial evaluating…
